A current review of olanzapine's safety in the geriatric patient: From pre-clinical pharmacology to clinical data

International Journal of Geriatric Psychiatry

Volumn 16, Issue SUPPL. 1, 2001, Pages

  Kennedy, John S ^a   Bymaster, Frank P ^a   Schuh, Leslie ^a   Calligaro, David O ^a   Nomikos, George ^a   Felder, Christian C ^a   Bernauer, Mark ^a   Kinon, Bruce J ^a   Baker, Robert W ^a   Hay, Donald ^a   Roth, H John ^a   Dossenbach, Martin ^a   Kaiser, Christopher ^a   Beasley, Charles M ^a   Holcombe, John H ^a   Effron, Mark B ^a   Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's dementia; Bipolar disorder; Dementia; Diabetes; Geriatric; Olanzapine; Receptors; Safety; Schizophrenia

Indexed keywords

DRUG DERIVATIVE; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PIRENZEPINE;

AGED; ALZHEIMER DISEASE; ANIMAL; BRAIN; DRUG EFFECT; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; HUMAN; NEUROLOGIC EXAMINATION; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ALZHEIMER DISEASE; ANIMAL; BRAIN; DRUG EVALUATION, PRECLINICAL; HUMAN; NEUROLOGIC EXAMINATION; PIRENZEPINE; RECEPTORS, NEUROTRANSMITTER; SUPPORT, NON-U.S. GOV'T;

EID: 0002219724     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1166(200112)16:1+<::aid-gps571>3.0.co;2-5     Document Type: Review

References (224)

1. Adler LA, Angrist B, Reiter S, et al. 1989. Neuroleptic-induced akathisis: a review. Psychopharmacol 97: 1-11.
2. Ala TA, Frey WH. 1995. Validation of the NINCDS-ADRDA criteria regarding gait in the clinical diagnosis of Alzheimer disease. A clinicopathologic study. Alzheimer Dis Assoc Disord 9: 152-159.
3. Alli C, Avanzini F, Betteli G, et al. 1992. Prevalence and variability of orthostatic hypotension in the elderly. Results of the 'Italian study on blood pressure in the elderly (SPAA)'. The 'Gruppo de Studio Sulla Pressione Arteriosa nell' Anziono'. Eur Heart J 13: 178-182.
4. Allison DB, Casey DE. 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62: 22-31.
5. Allison DB, Cavazzoni P, Beasley CM Jr, Berg PH, Mukhopadhyay N, Mallinckrodt C, et al. 2001. Random blood glucose levels in patients treated with schizophrenia treated with typical and atypical antipsychotic agents: an analysis of data from double-blind, randomized, controlled clinical trials. International Congress on Schizophrenia Research, Whistler, BC, May, 2001.
6. Allison DB, Mentore JL, Heo M, et al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
7. Altman DG, Schultz KF, Moher D, et al. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
8. American Diabetes Association Screening for Type 2 Diabetes. 2000. Diabetes Care 23: S1-S116.
9. Avery EE, Baker LD, Asthana S. 1997. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 11: 450-459.
10. Azorin J-M, Spiegel R, Remington G, Vanelle J-M, Pere J-J, Giguere M, Bourdeix I. 2001. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 158: 1305-1313.
11. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
12. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. 2001. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62: 231-238.
13. Bazett HC. 1920. An analysis of the time relations of electrocardiograms. Heart 7: 353-370.
14. Beasley CM, Kwong K, Berg PH, Taylor CC, Dananberg J, Breier A. 2000. Incidence and rate of treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Presented at the American College of Neuropsychopharmacology, San Juan, PR, January, 2000.
15. Beasley CMJr, Dellva MA, Tamura RN, et al. 1999. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 17-4: 23-30.
16. Beasley CM Jr, Tollefson G, Tran P. 1997. Safety of olanzapine. J Clin Psychiatry 58(suppl. 10): 13-17.
17. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. 2001. The QT interval. Progress Cardiovas Dis 43(Suppl. 1): 1-45.
18. Bein H. 1997. Prejudices in pharmacology and pharmacotherapy. The so-called anticholinergic effect of antidepressants. Agents Actions 7: 313-315.
19. Beyer JL, Siegal A, Kennedy JS, et al. 2001. Olanzapine, divalproex, and placebo treatment non-head-to-head comparisions of older adult acute mania. Annual Meeting of the International Congress of the Psychogeriatric Association, Nice, France. September, 2001.
20. Blaum C, Fries B, Fiatarone M. 1995. Factors associated with low body mass index and weight loss in nursing home residents. J Gerontol A Biol Sci Med 50: M162-M168.
21. Bonora E, Kiechl S, Oberhollenzer F, et al. 2000. Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 43: 156-164.
22. Borman R, Burleigh D. 1996. Human colonic mucosa posseses a mixed population of 5-HT receptors. Eur J Pharmacol 309: 271-274.
23. Bouchard RH, Demers MF, Simoneau I, et al. 2001. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 21: 110-111.
24. Boyd L, Dwyer J, Papas A. 1997. Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. Nutr Rev 55: 362-368.
25. Braceland FJ, Medena LJ, Vaichulis JA. 1945. Delayed action of insulin in schizophrenia. Am J Psychiatry 102: 108-110.
26. Breier A, Tanaka Y, Roychowdhury S, Clark WS. 2001. Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders: a randomized controlled double blind study. Presented at the annual meeting of the American Psychiatric Association, New Orleans, LA, May, 2001.
27. Briejer MR, Akkermans LM, Lefebvre RA, Schuurkes JA. 1995a. Novel 5-HT2-like receptor mediates neurogenic relaxation of the guinea-pig proximal colon. Eur J Pharmacol 279: 123-133.
28. Briejer MR, Akkermans LM, Schuurkes JA. 1995b. Interactions of serotonin with multiple receptors and neurotransmitters in the guinea-pig isolated colon. Arch Int Pharmacodyn Ther 329: 121-133.
29. Bueno-Cavanillas A, Padilla-Ruiz F, Jimenez-Moleon JS, Peinado-Alonso CA, Galvez-Vargas R. 2000. Risk factors in falls among the elderly according to extrinsic and intrinsic precipitating causes. Eur J Epidemiol 16: 849-859.
30. Byerly M, Greer R, Evans D. 1995. Behavioral stimulation associated with risperidone initiation. Am J Psychiatry 152: 1096-1097.
31. Bymaster F, Perry KW, Nelson DL, et al. 1999. Olanzapine: a basic science update. Br J Psychiatry 174: 36-40.
32. Bymaster FP, Calligaro DO, Falcone JF, et al. 1996. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14: 87-96.
33. Bymaster FP, Falcone JF. 2000. Decreased binding affinity of olanzapine and clozapine for clonal human muscarinic receptor subtypes in intact CHO cells in physiological medium. Eur J Pharmacol 390: 245-248.
34. Cacabelos R, Yamatodani A, Niigawa H, et al. 1989. Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol 11: 353-360.
35. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. 1999. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37: 177-193.
36. Campbell A. 1991. A review of the offending agents. Drugs Aging 1: 289-302.
37. Cavazzoni P, Baker RW, Kwong K, Hornbuckle K, Hutchins D, Jovanovic L, et al. 2001. A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States. Presented at the American Psychiatric Association. New Orleans, LA, May, 2001.
38. Centers for Disease Control and Prevention. Mortality from coronary heart disease and acute myocardial infarction - United States. 1998, 2001. J Am Med Ass 285: 1288.
39. Chengappa KNR, Pollock BG, Parepally H, et al. 1999. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20: 311-316.
40. Chiodo L, Bunney B. 1983. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and AlO midbrain dopaminergic neurons. J Neurosci 3: 1619.
41. Cohen J. 2000. In search of the underlying mechanisms of frailty. J Gerontol A Biol Sci Med 55: M706-M70S.
42. Conley RR, Mahmoud R. 2001. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158: 765-774.
43. Cools AR, Prinssen EP, Ellenbroek BA. 1995. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacol 119: 428-439.
44. Correa N, Opler L, Kay S, Birmaher B. 1987. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 7: 91-95.
45. Cottingham EM. 2000. Metformin leads to weight loss in adolescents who gained weight on psychotropic drugs. Poster presented at the annual meeting of the American Psychiatric Association, Chicago, IL, May, 2000.
46. Cowie C, Eberhardt M. 1996. Diabetes 1996 vital statistics. Am Diab Ass 13-20. Alexandria; VA.
47. Croakin P, Jacobs K, Bain B. 2000. Diabetic Ketoacidosis associated with risperidone treatment? Psychosomatics 41: 369-370.
48. Crumb WJ Jr, Beasley C Jr, Thornton A, Breier A. 1999. Cardiac ion channel blocking profile of olanzapine and other antipsychotics. Presented at the annual meeting of the American College of Neuropsychopharmacology, Acapulco, MX, December, 1999.
49. Cummings JL, Street JS, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dementia Geriatr Cog Disord, in press.
50. Czekalla J, Beasley CJ, Dellva M, et al. 2001. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 62: 191-198.
51. Daniel D, Zimbroff D, Potkin S, et al. 1999. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacol 20: 491-505.
52. DeVane CL. 1995. Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. Am J Health Syst Pharm 52(3 Suppl. 1): S15-S18.
53. Dewey RBJ, O'Suilleabhain PE. 2000. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55: 1753-1754.
54. Doig A, Sembhi S, Livingston G. 2000. Acute confusional states during treatment with risperidone. Int J Geriatr Psychiatry 15: 534-535.
55. Dursun S. 2000. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45: 198.
56. Eglen RM, Nahorski SR. 2000. The muscarinic M(5) receptor: a silent or emerging subtype? Br J Pharmacol 130: 13-21.
57. 2 muscarinic receptors in the guinea pig ileum. Life Sci 56: 965-971.
58. Elander G, Hermeren G. 1995. Placebo effect and randomized clinical trials. Theor Med 16: 171-182.
59. Erickson KA, Schroeder A. 2000. Direct effects of muscarinic agents on the outflow pathways in eyes. Invest Opthalmol Vis 41: 1743-1748.
60. Ernst ND, Obarzanek E, Clark MB, et al. 1997. Cardiovascular health risks related to overweight. J Am Dietetic Ass 97: S47-S51.
61. Fernandez HH, Friedman JH, Jacques C, et al. 1999. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14: 484-487.
62. Fernandez HH, Lannon MC, Friedman JH, Rosenfeld M. 2000. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15: 579-586.
63. Fisher A, Michaelson D, Brandeis R, Haring R, Chapman S, Pittel Z. 2000. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann N Y Acad Sci 920: 315-320.
64. Floris M, Lejeune J, Deberdt W. 2001. Effects of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 11: 181-182.
65. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. 1995. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64: 1888-1891.
66. Ford ES, Williamson DF, Liu S. 1997. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 146: 214-222.
67. Foss MC, Paula FJ, Pacoloa GM, Piccinato CE. 1995. Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol 43: 721-126.
68. Freeman H. 1946. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 56: 74-78.
69. Fridericia L. 1920. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 53: 469.
70. Friedman JH. 1991. The management of the levodopa psychoses. Clin Neuropharmacol 14: 283-295.
71. Friedman JH, Factor SA. 2000. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15: 201-211.
72. Fryburg DA, O'Sullivan RL, Siu C, Simpson G. 2001. Insulin resistance in olanzapine- and ziprasidone-treated patients: interim results of a double-blind controlled 6-week trial. Presented at the annual meeting of the American Psychiatric Association, New Orleans, LA, May, 2001.
73. Frye MA, Ketter TA, Altshuler LL, et al. 1998. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 48: 91-104.
74. Gait J, Smith S, Brown S. 2000. Evaluation of safety data from controlled clinical trials: the clinical principles explained. Drug Info J 34: 273-287.
75. Gants R. 1997. Detection and correction of underweight problems in nursing home residents. J Gerontolog Nurs 23: 26-31.
76. Garcia-Sainz J, Vazquez-Prado J, Villalobos-Molina R. 1999. Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res 30: 449-158.
77. Gardner C, Winkleby M, Fortmann S. 2000. Population frequency distribution of non-high-density lipoprotein cholesterol. Am J Cardiol 86: 299-304.
78. Garson A. 1993. How to measure the QT interval - What is normal? Am J Cardiol 72: 14B-16B.
79. Ghadirian AM, Annable L, Belanger MC, Choinard G. 1996. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57: 22-28.
80. Glazer W. 2000. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61: 16-21.
81. Glazer W. 2000. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61: 15-20.
82. Glick ID, Romano SJ, Simpson G, Horne RL, Weiden P, Pigott T, Bari M. 2001. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Annual meeting of the American Psychiatric Association, New Orleans, LA, May, 2001.
83. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurol 55: 789-794.
84. Gordon A, Price LH. 1999. Mood stabilization and weight loss with topiramate. Am J Psychiatry 156(6): 968-969.
85. Graf S, Sarna S. 1997. 5-HT-induced colonic contractions: enteric locus of action and receptor subtypes. Am J Physiol 273: G68-G74.
86. Guize L, Benetos A, Thomas F, Malmejac A, Ducimetiere P. 1998. Cholesterolemia and total, cardiovascular, and cancer mortality. Bull Acad Natl Med 182: 631-647.
87. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338 ed. US Department of Health, Education, and Welfare: Bethesda, MD.
88. Hall K, Luepker R. 2000. Is hypercholesterolemia a risk factor and should it be treated in the elderly? Am J Health Prom 14: 347-356.
89. Harris MI, Flegal KM, Cowie CC, et al. 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 21: 518-524.
90. Harris MI. 1995. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clinical Invest Med 18: 231-239.
91. Higuchi M, Yanai K, Okamura N, et al. 2000. Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neurosci 99: 721-729.
92. 1 receptors in guinea-pig brain. J Neurochem 31: 997-1004.
93. Hunt N, Silverstone T. 1988. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol 6: 45-50.
94. Jackson T, Ditmanson L, Phibbs B. 1997. Torsades de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013-2015.
95. Jarventausta K, Leinonen E, Andreassen M. 2000. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiat Scand 102: 231-233.
96. Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP. 1998. Adverse neurobiological effects of long-term use of neuroleptics in human and animal studies. J Psychiatr Res 32: 201-214.
97. Jeste DV. 2000. Tardive dyskinesia in older patients. J Psychiatr Res 32: 201-214.
98. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. 1998. Olanzapine can worsen parkinsonism. Neurol 50: 1183-1184.
99. Johnson V, Bruxner G. 1998. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 32: 884-886.
100. Kannel W. 2000. The Framingham Study: ITS 50-year legacy and future promise. J Atheroscler Thromb 6: 60-66.
101. Kapur S, Seeman P. 2001. Does fast dissociation from dopamine d(2) receptors explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158: 360-369.
102. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Marrissey MR. 1998. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol 140: 173-184.
103. Keller H. 1993. Malnutrition in the institutionalized elderly: how and why? J Am Geriatr Soc 41: 1212-1218.
104. Kennedy J, Bymaster FP, Basson B, Gilmore JA, Tran PV. 2000. The comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone. Primary Care Companion 2: 122-126.
105. Kennedy JS, Kwentus JA, Kumar V, Schmidt D. 1998. Cholinergic drugs in the treatment of Alzheimer's disease. In Advances in the Diagnosis and Treatment of Alzheimer's Disease, Kumar V, Eisdorfer C (eds). Springer Publishing Company: New York; 298-350.
106. Keskiner A, el-Toumi A, Bousquet T. 1993. Psychotropic drugs, diabetes, and chronic mental patients. Psychosomatics 14: 176-181.
107. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. 2000. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100.
108. Klemm W. 1989. Drug effects on active immobility responses: what they tell us about neurotransmitter systems and motor functions. Prog Neurobiol 32: 403-422.
109. Kostakoglu AE, Yazici KM, Erbas T, Guvener N. 1996. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatrica Scand 93: 217-218.
110. Koutsavlis A, Wolfson C. 2000. Elements of mobility as predictors of survival in elderly patient with dementia: findings from the Canadian Study of Health and Aging. Chronic Dis Can 21: 93-103.
111. Koval MS, Rames LJ, Christie S. 1994. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 151: 1520-1521.
112. Lamberti JS, Bellnier TJ, Schwarzkopf SB. 1992. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 149: 689-690.
113. Lane LM, Burns PR, Sanger TM, Beasley CM Jr, Tollefson GD. 1998. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders. 11th Annual Meeting of the European College of Neuropsychopharmacology, Paris, France, 1998.
114. Lawrence KR, Nasraway SA. 1997. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacother 17: 531-537.
115. Lazarus A. 1994. Tardive dyskinesia-like syndrome associated with lithium and carbamazepine [letter]. J Clin Psychopharmacol 14: 146-147.
116. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. 1992. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149: 68-72.
117. Leander JD, Gleason SD. 2001. Preclinical studies of olanzapine-induced weight gain. Presented at the annual meeting of the american Psychiatric Association, New Orleans, LA, May, 2001.
118. Ledru F, Ducimetiere P, Battaglia S, et al. 2001. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardio 37: 1543-1550.
119. Lee J, Robertson S. 1997. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann Clin Psychiatry 9: 165-169.
120. Levey AI. 1993. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52: 441-448.
121. Lim SC, Tai ES, Tan BY, Chew SK, Tan CE. 2000. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 23: 278-282.
122. Lin CC, Li TC, Lai SW, et al. 1999. Epidemiology of obesity in elderly people. Yale J Biol Med 72: 385-391.
123. Lindenmayer J-P, Patel R. 1999. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 156: 1471.
124. Lopez O, Wisnieski S, Becker J, et al. 1997. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 54: 969-975.
125. Lorenz WF. 1922. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8: 184-196.
126. Maguire G, Kennedy JS, Bymaster FP, et al. 2001. Acute double-blind comparison of olanzapine and haloperidol in patients with schizophrenia age ≥ 60. Annual Meeting of the International Congress of the Psychogeriatric Association, Nice, France. September, 2001.
127. Manson AJ, Schrag A, Lees AJ. 2000. Low-dose olanzapine for levodopa induced dyskinesias. Neurol 55: 795-799.
128. Marcus E-L, Vass A, Zislin J, Gonzalez L, Larouche M. 1999. Marked elevation of serum creatine kinase associated with olanzapine therapy. Annals Pharmacother 33(6): 697-700.
129. Mayfield J. 1998. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician 58: 1355-1362.
130. McCormack P. 1997. Undernutrition in the elderly population living at home in the community: a review of the literature. J Adv Nurs 26: 856-863.
131. McGowan B, Heerey A, Ryan M, Walsh M, Feely J, Barry M. 2000. Cost of treating heart failure in an Irish teaching hospital. Irish J Med Sci 169: 241-244.
132. McKee HA, D'Arcy PF, Wilson PJ. 1986. Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm 11: 297-299.
133. Melamed Y, Mazek D, Elizur A. 1998. Risperidone treatment for a patient suffering from schizophrenia and IDDM. Can J Psychiatry 43: 956.
134. Melkersson K, Hulting A, Brismar K. 2000. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749.
135. Metcalf P, Scragg R. 2000. Comparison of WHO and ADA criteria for diagnosis of glucose status in adults. Diabetes Res Clin Pract 49: 169-180.
136. Mets T. 1995. Drug-induced orthostatic hypotension in older patients. Drugs Aging 6: 219-228.
137. Mir S, Taylor D. 2001. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 16: 63-73.
138. Mokdad A, Ford E, Bowman B, et al. 2000. Diabetes trends in the US, 1990-1998. Diabetes Care 23: 1278-1283.
139. Molho ES, Factor SA. 1999. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 14: 1014-1016.
140. Moore NA, Leander JD, Benvenga MJ, et al. 1997. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58: 37-44.
141. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. 1991. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67: 774-776.
142. Morley J, Kraenzle D. 1994. Causes of weight loss in a community nursing home. J Am Geriatr Soc 42: 583-585.
143. Morris R, Rimm D, Hartz A. 1989. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women. Am J Epidemiol 130: 121.
144. Mortality from coronary heart disease and acute myocardial infarction - United States. 1998, 2001. Morbidity and Mortality Weekly Report 50: 90-93.
145. Moss AJ. 1993. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 72: 23B-25B.
146. Mukherjee S, Rosen AM, Caracci G, Shukla S. 1986. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 43: 342-346.
147. Mukherjee S, Schnur DB, Reddy R. 1989. Family history of type 2 diabetes in schizophrenic patients [letter]. Lancet 1: 495.
148. Mukherjee S. 1995. High prevalence of type II diabetes in schizophrenic patients. Schizophr Res 15: 195.
149. Muscettola G, Barbato G, Pampallona S. 1999. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, association with tardive dyskinesia. J Clin Psychopharmacol 19: 203-208.
150. Mutschler E, Moser U, Wess J, Lambrecht G. 1995. Muscarinic receptor subtypes - pharmacological, molecular biological and therapeutic aspects. Pharm Acta Helv 69: 243-258.
151. Nagakura Y, Kamato T, Nishida A, Ito H, Yamand M, Miyata K. 1996. Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs. Naunyn Schmiecebergs Arch Pharmacol 353: 489-498.
152. Nasif FJ, Cuadra GR, Ramirez OA. 2000. Effects of chronic risperidone on central noradrenergic transmission. Eur J Pharmacol 394: 67-73.
153. Nath C, Gulati A, Dhawan K, et al. 1988. Role of histaminergic mechanism in behavioural depression (swimming despair) in mice. Life Sci 42: 2413-2417.
154. National Diabetes Data Group. 1995. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, second edn. Bethesda, MD; 179-220.
155. NCEP. 2001. Executive Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Treatment Panel III. J Am Med Ass 285: 2486-2497.
156. Newman A, Gottdiener J, Mcburnie M. 2001. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med 56: M158-M166.
157. Nguyen CTTS. 2001. Nutritional education in minimizing weight gain associated with antipsychotic therapy. Annual meeting of the American Psychiatric Association, New Orleans, LA, May, 2001.
158. Nickens H. 1985. Intrinsic factors in falling among the elderly. Arch Intern Med 145: 1089-1093.
159. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T. 1990. Torsade de pointes with T wave alternans in a patient receiving a moderate dose of chlorpromazine: report of a case. Kokyu To Junkan 38: 819-822.
160. Osser D, Najarian D, Dufresne R. 1999. Olanzapine increases weight and serum triclyceride levels. J Clin Psychiatry 60: 767-770.
161. Pang IH, Matsumoto S, Tamm E, Desantis L. 1994. Characterization of muscarinic receptor involvement in human ciliary muscle cell function. J Ocular Pharmacol 10: 125-136.
162. Paoloni P, Cilibert D, Blasi N, Capone P. 1992. Iatrogenic torsade de pointes induced by thioridazine. Minerva Cardioangiol 40: 245-249.
163. Pelonero AL, Levenson JL, Pandurangi AK. 1998. Neuroleptic malignant syndrome: a review. Psychiatr Serv 49: 1163-1172.
164. Penttila J, Syvalahti E, Hinkka S, Kuusela T, Scheinin H. 2001. The effects of amitryptyline, citalopram and reboxetine on autonomic nervous system. A randomized placebo-controlled study on healthy volunteers. Psychopharmacol 154: 343-349.
165. Perry E, Haroutunian V, Davis K, et al. 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5: 747-749.
166. Pfizer Pharmaceuticals. 2000. FDA psychopharmacological drugs advisory committee briefing document for Zeldox® capsules (Ziprasidone HCl) Zeldox NDA 20-825. Briefing document for the US FDA Psychopharmalogical Drug Advisory Committee. July. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/361961a.pdf; 7-19.
167. Physician's Desk Reference to Pharmaceutical Specialties and Biologics. 2001. Sifton DW, Murray L, Kelly GL (eds). Medical Economics Company: Oradell, NJ.
168. Pitner J, Mintzer J, Pennypacker L, Jackson CW. 1995. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 56: 180-185.
169. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskin GE. 1997. Clozapine and associated diabetes mellitus. J Clin Psychiatry 58: 108-111.
170. Purdon SE, Jones BD, Slip E, et al. 2000. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249-258.
171. Ravin D, Levenson J. 1997. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 31: 867-870.
172. Ravona-Springer R, Dolberg O, Hirschmann S, et al. 1998. Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol 18: 171-172.
173. Rewers M, Hamman R. 1995. Risk factors for non-insulin dependent diabetes. National Institutes of Health: 220.
174. Rigalleau V, Gatta B, Bonnaud S, Barth N, Gin H. 2000. Diabetes as a result of atypical antipsychotic drugs: a report of three cases. Diabetic Med 17: 484-486.
175. Roberts S, Fuss P, Heyman M, et al. 1996. Effects of age on energy expenditure and substrate oxidation during experimental underfeeding in healthy men. J Gerontol A Biol Sci Med 51: B158-B166.
176. Ros E. 2000. Intestinal absorption of tryglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151: 357-379.
177. 2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 48: 167-168.
178. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. 2001. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open label continuation phase study. J Clin Psychiatry 62: 273-281.
179. Satterlee W, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD. 1995. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 31: 534.
180. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 39: 486-487.
181. Schweitzer I, Burrows G, Tuckwell V, et al. 2001. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 21: 185-189.
182. Seeman P, Trallerico T. 1999. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156(6): 876-884.
183. Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y. 1999. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 55: 583-587.
184. Sempos CT, Cleeman JL, Carroll MD. 1993. Prevalence of high blood cholesterol among US adults. JAMA 69: 3009.
185. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. 1998. Torsades de pointes associated with intravenous haloperidol in ill patients. Am J Cardiol 81: 238-240.
186. Sheitman B, Bird P, Binz W. 1999. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 156: 1471-1472.
187. Silver A, Morley J, Strome L, et al. 1998. Nutritional status in an academic nursing home. J Am Geriatr Soc 36: 487-491.
188. Silver AJ, Morley JE, Strome LS, Jones D, Vickers L, Henderson CT. 1990. Nutrition. In Geriatric Mediine (2nd edn), Cassels CK, Riesenberg DE, Sorenson LB, Walsh JR (eds). Springer-Verlag: New York; 535-554.
189. Sim F, Brunet D, Conacher G. 2000. Quetiapine associated with acute mental status changes. Can J Psychiatry 45: 299.
190. Simpson G, Romano SJ, Horne RL, Weiden P, Pigott T, Bari M. 2001. Ziprasidone versus olanzapine in schizophrenia: results of a double-blind trial. Annual meeting of the American Psychiatric Association, New Orleans, LA, May, 2001.
191. Simpson GM, Angus JWS. 1970. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 212: S11-S19.
192. SkarsfeldtT. 1995. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289-294.
193. Sobel M, Jaggers E, Franz M. 1999. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 60: 556-557.
194. Spencer C, Gunasekara N, Hills C. 1999. Zolmitriptan: a review of its use in migraine. Drugs 58: 347-374.
195. Spooner J, Lapane K, Hume A, Mucha L, Straus WL. 2001. Pharmacologic treatment of diabetes in long-term care. J Clin Epidem 54: 525-539.
196. Stanilla JK, deLeon J, Simpson GM. 1997. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 58: 252-255.
197. Stanniland C, Taylor D. 2000. Tolerability of atypical antipsychotics. Drug Saf 22: 195-214.
198. Stoa-Birketvedt G, Paus P, Ganss R, Ingibretsen OC, Florhozmen S. 1998. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int Acad Biomed Drug Res 22: 1041-1045.
199. Stockton ME, Rasmussen K. 1996. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol 14: 97-105.
200. Street JS, Clark WS, Gannon KS, et al. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57: 968-976.
201. Sunderland T, Tariot PN, Cohen RM, et al. 1987. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 44: 418-426.
202. 2C serotonin receptors. Nature 374: 542-546.
203. Teuscher A, Reinli K, Teuscher A. 2001. Gylcaemia and insulinaemia in elderly European subjects (70-75 years). Diabetic Med 18: 150-153.
204. Thomas D, Verdery R, Gardner L, Kant A, Lindsay J. 1991. Prospective study of outcomes form protein-energy malnutrition in nursing home residents. J Parent Ent Nutr 15: 400-404.
205. Thonnard-Neumann E. 1968. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 7: 978-982.
206. Tohen M, Jacobs TG, Grundy SL, et al. 2000. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 57: 841-849.
207. Tohen M, Sanger TM, McElroy SL, et al. 1999. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 156: 702-709.
208. Tollefson G, Lesar T. 1983. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry 44: 347-348.
209. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. 1997a. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248-1254.
210. Tollefson GD, Beasley CM Jr, Tran PV, et al. 1997b. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4): 457-465.
211. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. 2001. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49: 52-63.
212. Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, Tollefson GD. 2000. Olanzapine (Zyprexa): A Novel Antipsychotic. Lippincott Williams & Wilkins: Philadelphia, PA.
213. Tran PV, Hamilton SH, Kuntz AJ, et al. 1997. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-418.
214. Tresch D. 2001. Evaluation and management of cardiac arrhythmias in the elderly. Med Clin North Am 85: 527-550.
215. Van Rossum C, Shipley M, van de Mheen H, Grobbee DE, Marmot MG. 2000. Employment grade differences in cause specific mortality. A 25 year follow up of civil servants from the first Whitehall study. J Epidemiol Community Health 54: 178-184.
216. Verhaeverbeke I, Mets T. 1997. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17: 265-268.
217. Waddington JL, Youssef HA. 1988. Tardive dyskinesia in bipolar affective disorder: aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium. Am J Psychiatry 145: 613-616.
218. Wing LM, Tonkin AL. 1997. Orthostatic blood pressure control and ageing. Aust N Z J Med 27: 466.
219. Wirshing DA, Spellberg BJ, Erhart SM, Weinbach J, Wirshing WC. 1998. Novel antipsychotics and new onset diabetes. Biol Psychiatry 44: 778-783.
220. Wirshing DA, Wirshing WC, Kysar L, et al. 1999. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60: 358-363.
221. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. 1996. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurol 47: 1085-1087.
222. Yasuda R, Ciesla W, Flores L, et al. 1993. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43: 149-157.
223. Young C, Bowers MB Jr, Mazure CM. 1998. Management of the adverse effects of clozpine. Schizophr Bull 24: 301-390.
224. Zisook S, Chentsova-Dutton Y, Smith-Vaniz A, et al. 2000. Nefazodone in patients with treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 61: 203-208.